Refractory Flt3-Mutated Acute Myeloid Leukemia

Naval Daver, MD, spoke with Healio about updates in FLT3-mutated acute myeloid leukemia from Society of Hematologic Oncology Annual Meeting.

Gilteritinib and quizartinib were well-tolerated and linked to improved survival and treatment response compared with salvage chemotherapy for relapsed or refractory FLT3 internal tandem duplication-mutated acute myeloid leukemia.

ORLANDO — Quizartinib significantly prolonged survival compared with salvage chemotherapy among patients with relapsed or refractory acute myeloid leukemia and high FLT3-internal tandem duplication variant allele frequency, according to prospective results presented at ASH Annual Meeting and Exposition.